Brokerages Set Xencor, Inc. (NASDAQ:XNCR) PT at $36.56

Xencor, Inc. (NASDAQ:XNCR) has been assigned an average rating of “Buy” from the nine analysts that are covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $36.56.

Several equities analysts recently issued reports on XNCR shares. Wells Fargo & Company initiated coverage on Xencor in a report on Thursday, December 12th. They set an “overweight” rating and a $37.00 price objective for the company. JPMorgan Chase & Co. lifted their price target on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Wedbush reissued an “outperform” rating and issued a $38.00 price objective on shares of Xencor in a research note on Thursday, November 7th. Royal Bank of Canada raised their target price on shares of Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, September 26th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $34.00 price target (up previously from $32.00) on shares of Xencor in a report on Friday, November 8th.

Insider Activity at Xencor

In other Xencor news, CEO Bassil I. Dahiyat sold 3,366 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $24.02, for a total value of $80,851.32. Following the sale, the chief executive officer now directly owns 352,615 shares of the company’s stock, valued at approximately $8,469,812.30. This trade represents a 0.95 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Alan Bruce Montgomery sold 13,301 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $27.03, for a total transaction of $359,526.03. Following the transaction, the director now directly owns 9,140 shares of the company’s stock, valued at approximately $247,054.20. This represents a 59.27 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 136,050 shares of company stock valued at $3,277,609. Company insiders own 5.23% of the company’s stock.

Hedge Funds Weigh In On Xencor

A number of large investors have recently bought and sold shares of XNCR. Primecap Management Co. CA grew its stake in shares of Xencor by 0.3% during the 2nd quarter. Primecap Management Co. CA now owns 9,116,202 shares of the biopharmaceutical company’s stock valued at $172,570,000 after buying an additional 25,495 shares during the period. Point72 Asset Management L.P. grew its position in Xencor by 147.3% during the third quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock valued at $62,748,000 after acquiring an additional 1,858,440 shares during the period. Logos Global Management LP increased its stake in Xencor by 130.8% during the second quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock worth $28,395,000 after acquiring an additional 850,000 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Xencor by 6.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,459,427 shares of the biopharmaceutical company’s stock worth $27,628,000 after purchasing an additional 87,979 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Xencor by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company’s stock valued at $29,273,000 after purchasing an additional 17,658 shares in the last quarter.

Xencor Stock Up 2.1 %

Shares of NASDAQ XNCR opened at $25.04 on Friday. The stock has a market capitalization of $1.75 billion, a price-to-earnings ratio of -7.65 and a beta of 0.69. Xencor has a 52 week low of $15.31 and a 52 week high of $27.24. The firm has a 50-day moving average price of $23.13 and a 200 day moving average price of $20.65. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27. The company had revenue of $10.70 million during the quarter, compared to analysts’ expectations of $14.59 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm’s quarterly revenue was down 81.9% compared to the same quarter last year. During the same period last year, the company posted ($0.40) earnings per share. Equities research analysts anticipate that Xencor will post -3.71 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.